Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 8/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | METAP2 | P50579 | 2/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | FLT4 | P35916 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.45 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.45 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12991398 | 0.78 | PTGER4 (0.67) | PTGER4HPGDALDH1A1 | |
| SCHEMBL10765828 | 0.74 | KDM4E (0.72) | HPGDALDH1A1L3MBTL1KDM4EEGFR | |
| SCHEMBL3534150 | 0.74 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL3534146 | 0.74 | PTGER4 (0.59) | PTGER4HPGDALDH1A1KDM4EFLT1 | |
| SCHEMBL3540821 | 0.73 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL3535945 | 0.72 | KDM4E (0.52) | PTGER4HPGDKDM4EEGFRFLT1 | |
| SCHEMBL653805 | 0.71 | FLT1 (0.77) | HPGDALDH1A1KDM4EEGFRFLT1 | |
| SCHEMBL1412654 | 0.71 | POLB (0.71) | HPGDKDM4EEGFRFLT1FLT4 | |
| SCHEMBL13841825 | 0.70 | PTGER4 (0.68) | PTGER4HPGDALDH1A1L3MBTL1KDM4E | |
| SCHEMBL28176964 | 0.70 | RAB9A (0.56) | HPGDALDH1A1L3MBTL1KDM4EPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100408570-C | EP4 receptor antagonists | PHARMAGENE LAB LTD (GB) | 2008-08-06 | — | — | CN | claimed |
| EP-1603893-B1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2008-05-21 | — | — | EP | claimed |
| US-7858644-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| US-7528157-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-7507754-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-03-24 | — | — | US | disclosed |
| CN-100408570-C | EP4 receptor antagonists | PHARMAGENE LAB LTD (GB) | 2008-08-06 | — | — | CN | disclosed |
| EP-1603893-B1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2008-05-21 | — | — | EP | disclosed |
| US-20080039502-A1 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| US-20070123575-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK ACQUISITION LIMITED (GB) | 2007-05-31 | — | — | US | disclosed |
| US-7196089-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| CN-1761657-A | EP4 receptor antagonists | PHARMAGENE LAB LTD (GB) | 2006-04-19 | — | — | CN | disclosed |
| EP-1603893-A1 | EP4 RECEPTOR ANTAGONISTS | Pharmagene Laboratories Ltd (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-20040192767-A1 | EP4 receptor antagonists | ASTERAND UK ACQUISITION LIMITED (GB) | 2004-09-30 | — | — | US | disclosed |
| WO-2004067524-A1 | EP4 RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, NR4A1, NR4A2 | PTGER4 1/4885HPGD 618/4885ALDH1A1 1522/4885 |
| US-20040192767-A1 | EP4 receptor antagonists | PTGER4, PTGER1, NR4A1 | PTGER4 1/4885HPGD 621/4885ALDH1A1 1258/4885 |
| US-20070123575-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, NR4A1, PTGER1 | PTGER4 1/4885HPGD 628/4885ALDH1A1 1424/4885 |
| US-20080039502-A1 | EP4 receptor antagonists | PTGER4, NR4A1, PTGER1 | PTGER4 1/4885HPGD 645/4885ALDH1A1 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.